Nuvation Bio rises as B. Riley starts at Buy on launch trajectory for lead drug Nov. 19, 2025 2: 17 PM ETNuvation Bio Inc. climbed ~48% on Wednesday after B. Riley Securities launched its coverage with a Buy recommendation and a $12 per share target, citing early signs of a successful commercial rollout for Ibtrozi (taletrectinib), NUVB’s lead asset. Recommended For You More Trending News.
https://seekingalpha.com/news/4524051-nuvation-bio-stock-initiated-buy-b-riley?feed_item_type=news
Nuvation Bio rises as B. Riley starts at Buy on launch trajectory for lead drug
Byadmin
Nov 19, 2025